A significant number of cystic fibrosis (CF) patients do not receive timely lung transplant evaluations because of their preference and their doctors’ possibly too-narrow focus, according to the results of a survey. The study explaining the results, “Cystic fibrosis physicians’ perspectives on the timing of referral for lung transplant…
News
Drugs targeting a component of biofilm — the glue-like layer secreted by bacteria in cystic fibrosis (CF) patients’ lungs — could increase the bacteria’s vulnerability to antibiotics and natural immune reactions, according to a new study. Researchers discovered that a specific carbohydrate in biofilm — Psl — makes it stiffer and,…
Researchers at the University of Wisconsin–Madison have developed a technique that makes it possible to watch gene-editing processes in real time — which could help them understanding why editing attempts succeed or fail. The team, which received a $1.8 million grant from the National Institutes of Health (NIH), is now working to…
The Cystic Fibrosis Foundation (CFF) joined 72 other organizations, each advocating for patients with chronic, rare and life-threatening diseases, in an open letter to President Donald Trump and leaders in Congress. The letter asks that patients’ needs be taken into consideration as lawmakers revise current healthcare policies. Other groups joining this initiative include the Pulmonary Fibrosis…
A mouse model that reproduces the human symptoms of cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) gives scientists a new way to study, and perhaps develop treatments for, the diseases, according to new research. Researchers at Kumamoto University in Japan developed the model, then tested it to see how…
The U.S. Food and Drug Administration (FDA) has designated Concert Pharmaceuticals‘ next-generation therapy, CTP-656, an Orphan Drug to treat cystic fibrosis (CF). CTP-656 is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator that, according to the company’s website, was developed by applying deuterium chemistry to modify Kalydeco (ivacaftor). Concert has said…
The Cystic Fibrosis Foundation has announced the recipients of its first Impact Grants, which support individuals or organizations that positively impact the cystic fibrosis (CF) community. The winners will each receive $10,000. “People with CF have the greatest insights about how to live with this disease,” Drucy Borowitz, MD, vice…
The U.S. Food and Drug Administration (FDA) has designated PUR1900 a Qualified Infectious Disease Product (QIDP) as a potential treatment of fungal infections in the lungs of patients with cystic fibrosis(CF), its developer, Pulmatrix, announced. This designation accelerates the development of new treatments against infectious agents, and protects the exclusivity of PUR1900 for…
The first patients have been dosed in the Phase 2 clinical trial evaluating NovaBiotics‘ Lynovex (NM001, cysteamine) as an adjunct therapy for infectious exacerbations in cystic fibrosis (CF). CARE-CF (NCT03000348, NBTCS-02) is a randomized, double-blind, parallel group, and placebo-controlled study designed to investigate the optimal dose…
A deeper understanding of how a bacterial enzyme works to degrade the protective layer that surrounds bacteria, helping it to adhere to tissues and to grow and spread, may offer new ways of treating persistent Pseudomonas aeruginosa lung infections in patients with cystic fibrosis (CF). The study, “Biological function of…
Your CF Community
Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.